Members

  First name: Laurent
  Last name: Massias
  Function: Pharmacologist - Researcher
  Position: Hospital practitioner
  Email: laurent.massias
._
_.
inserm.fr

Research interest



Education

Degree

1996 : Ph. D. in Pharmaceutical Sciences, Paris Sud University
1990 : Pharm D. in Pharmaceutical Sciences, Paris Sud University
1979-1984 : Pharmaceutical school, Paris Sud University

Research training (post doctoral)

2013 – today : Member of research team, IAME, Paris Diderot University.

Exhaustive list of publications

2019


Pourbaix A, Guérin F, Burdet C, Massias L, Chau F, Cattoir V, Fantin B
Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.
Antimicrobial Agents and Chemotherapy 2019, 63,

Burdet C, Grall N, Linard M, Bridier-Nahmias A, Benhayoun M, Bourabha K, Magnan M, Clermont O, d'Humières C, Tenaillon O, Denamur E, Massias L, Tubiana S, Alavoine L, Andremont A, Mentré F, Duval X, CG
Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.
Antimicrobial Agents and Chemotherapy 2019, 63,

2018


Peiffer-Smadja N, Abbara S, Rizk N, Pogliaghi M, Rondinaud E, Tesmoingt C, Massias L, Lucet JC, Alkhoder S, Armand-Lefèvre L, Lescure FX
High-dose daptomycin in patients with infective endocarditis or sternal wound infections.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2018, 24, 1106-1108.

Argy N, Le Gal S, Coppée R, Song Z, Vindrios W, Massias L, Kao WC, Hunte C, Yazdanpanah Y, Lucet JC, Houzé S, Clain J, Nevez G
Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 67, 913-919.

Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1108-1110.

Reissier S, Saleh-Mghir A, Guerin F, Massias L, Ghout I, Sinel C, Cattoir V, Cremieux AC
In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.
The Journal of Antimicrobial Chemotherapy 2018, 73, 981-986.

Berleur M, Guérin F, Massias L, Chau F, Poujade J, Cattoir V, Fantin B, de Lastours V
Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli.
The Journal of Antimicrobial Chemotherapy 2018, 73, 3074-3080.

La Combe B, Mahérault AC, Messika J, Billard-Pomares T, Branger C, Landraud L, Dreyfuss D, Dib F, Massias L, Ricard JD
Oropharyngeal Bacterial Colonization after Chlorhexidine Mouthwash in Mechanically Ventilated Critically Ill Patients.
Anesthesiology 2018, 129, 1140-1148.

Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX, Csg
Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.
BMJ open 2018, 8, e023151.

2017


Atchade E, Jean-Baptiste S, Houzé S, Chabut C, Massias L, Castier Y, Brugière O, Mal H, Montravers P
Fatal invasive aspergillosis caused by Aspergillus niger after bilateral lung transplantation.
Medical Mycology Case Reports 2017, 17, 4-7.

Vindrios W, Argy N, Le Gal S, Lescure FX, Massias L, Le MP, Wolff M, Yazdanpanah Y, Nevez G, Houze S, Dorent R, Lucet JC
Outbreak of Pneumocystis jirovecii Infection Among Heart Transplant Recipients: Molecular Investigation and Management of an Interhuman Transmission.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2017, 65, 1120-1126.

Robin C, Lê MP, Melica G, Massias L, Redjoul R, Khoudour N, Leclerc M, Beckerich F, Maury S, Hulin A, Cordonnier C
Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2602-2606.

2016


Alexandre K, Chau F, Guérin F, Massias L, Lefort A, Cattoir V, Fantin B
Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli.
The Journal of Antimicrobial Chemotherapy 2016

2015


Burdet C, Pajot O, Couffignal C, Armand-Lefèvre L, Foucrier A, Laouénan C, Wolff M, Massias L, Mentré F
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
European Journal of Clinical Pharmacology 2015, 71, 75–83.

Burdet C, Pajot O, Couffignal C, Armand-Lefèvre L, Foucrier A, Laouénan C, Wolff M, Massias L, Mentré F
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
European Journal of Clinical Pharmacology 2015, 71, 75-83.

Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466–1472.

Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1466-1472.

Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, Da Silva D, Lasocki S, Laouénan C, Mentec H, Mentré F, Wolff M
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1487–1494.

Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, Da Silva D, Lasocki S, Laouénan C, Mentec H, Mentré F, Wolff M
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1487-1494.

Lecefel C, Eloy P, Chauvin B, Wyplosz B, Amilien V, Massias L, Taburet AM, Francois H, Furlan V
Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.
Journal of Clinical Pharmacy and Therapeutics 2015, 40, 119-120.

Welsch C, Augustin P, Allyn J, Massias L, Montravers P, Allou N
Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation.
Transplant Infectious Disease: An Official Journal of the Transplantation Society 2015, 17, 103-105.

Rossi B, Soubirou J, Chau F, Massias L, Dion S, Lepeule R, Fantin B, Lefort A
Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Antimicrobial Agents and Chemotherapy 2015, 32, 1708.

2014


de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R
Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.
Intensive Care Medicine 2014, 40, 998-1005.

Couffignal C, Pajot O, Laouénan C, Burdet C, Foucrier A, Wolff M, Armand-Lefevre L, Mentré F, Massias L
Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
British Journal of Clinical Pharmacology 2014, 78, 1022–1034.

Couffignal C, Pajot O, Laouénan C, Burdet C, Foucrier A, Wolff M, Armand-Lefevre L, Mentré F, Massias L
Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
British Journal of Clinical Pharmacology 2014, 78, 1022-1034.

Bourgeois-Nicolaos N, Nguyen TT, Defrance G, Massias L, Alavoine L, Lefort A, Noel V, Senneville E, Doucet-Populaire F, Mentré F, Andremont A, Duval X
The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
Antimicrobial Agents and Chemotherapy 2014, 58, 2681–2687.

Bourgeois-Nicolaos N, Nguyen TT, Defrance G, Massias L, Alavoine L, Lefort A, Noel V, Senneville E, Doucet-Populaire F, Mentré F, Andremont A, Duval X
The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
Antimicrobial Agents and Chemotherapy 2014, 58, 2681-2687.

Réminiac F, Sonneville R, Massias L, Chochillon C, Wolff M
Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid.
Antimicrobial Agents and Chemotherapy 2014, 58, 3568-3569.

2013


Grall N, Massias L, Nguyen TT, Sayah-Jeanne S, Ducrot N, Chachaty E, de Gunzburg J, Andremont A
Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.
Antimicrobial Agents and Chemotherapy 2013, 57, 5423–5425.

Grall N, Massias L, Nguyen TT, Sayah-Jeanne S, Ducrot N, Chachaty E, de Gunzburg J, Andremont A
Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.
Antimicrobial Agents and Chemotherapy 2013, 57, 5423-5425.

Guillard T, Cambau E, Chau F, Massias L, de Champs C, Fantin B
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Antimicrobial Agents and Chemotherapy 2013, 57, 5830-5835.

2012


Pang KAP, Godet C, Fekkar A, Scholler J, Nivoix Y, Letscher-Bru V, Massias L, Kauffmann-Lacroix C, Elsendoorn A, Uzunov M, Datry A, Herbrecht R
Breakthrough invasive mould infections in patients treated with caspofungin.
The Journal of Infection 2012, 64, 424-429.

Saleh-Mghir A, Dumitrescu O, Dinh A, Boutrad Y, Massias L, Martin E, Vandenesch F, Etienne J, Lina G, Crémieux AC
Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.
Antimicrobial Agents and Chemotherapy 2012, 56, 6291-6297.

Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Antimicrobial Agents and Chemotherapy 2012, 56, 1376-1381.

2009


Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentré F
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.
The Journal of Infectious Diseases 2009, 200, 390-398.

Allou N, Cambau E, Massias L, Chau F, Fantin B
Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.
Antimicrobial Agents and Chemotherapy 2009, 53, 4292-4297.

2003


Camus M, Hennere G, Baron G, Peytavin G, Massias L, Mentre F, Farinotti R
Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.
European Journal of Clinical Pharmacology 2003, 59, 583-587.